Biblio
Export 1711 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is C [Clear All Filters]
“Better Objective Sleep Quality in Older Adults with High Subjective Memory Decline.”, J Alzheimers Dis, vol. 53, no. 3, pp. 943-53, 2016.
, “Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.”, J Alzheimers Dis, vol. 54, no. 1, pp. 307-24, 2016.
, “Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.”, J Alzheimers Dis, vol. 53, no. 2, pp. 535-46, 2016.
, “Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly.”, J Alzheimers Dis, vol. 52, no. 2, pp. 561-72, 2016.
, “Brain Metabolism Correlates of the Free and Cued Selective Reminding Test in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 1, pp. 27-31, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 54, no. 2, pp. 793-9, 2016.
, “A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults.”, J Alzheimers Dis, vol. 54, no. 2, pp. 793-9, 2016.
, “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
, “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.
, “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.
, “Cerebral Amyloid Angiopathy (CAA)-Related Inflammation: Comparison of Inflammatory CAA and Amyloid-β-Related Angiitis.”, J Alzheimers Dis, vol. 51, no. 2, pp. 525-32, 2016.
, “Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 351-7, 2016.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
, “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
, “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
, “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer's Disease and Cerebrovascular Disease.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1073-1084, 2016.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
,